CAS: 1952272-74-0
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Bemarituzumab REF: TM-T76673CAS: 1952272-74-0 | SDS-PAGE:95% SEC-HPLC:99.99% | 185.00 €~2,219.00 € | Thu 05 Dec 24 |
 | Bemarituzumab REF: 3D-CLA1499CAS: 1952272-74-0 | - - - | To inquire | Tue 17 Dec 24 |
Bemarituzumab
CAS:1952272-74-0
Bemarituzumab: humanized IgG1 antibody inhibits FGFR2b, may be used in cancer research.
Purity:
SDS-PAGE:95% SEC-HPLC:99.99%
Color and Shape:
Liquid
Molecular weight:
144 kDa
Ref: TM-T76673
| 1mg | 185.00 € | ||
| 5mg | 502.00 € | ||
| 10mg | 802.00 € | ||
| 25mg | 1,203.00 € | ||
| 50mg | 1,633.00 € | ||
| 100mg | 2,219.00 € |
Estimated delivery in United States, on Thursday 5 Dec 2024
Bemarituzumab
CAS:1952272-74-0
Humanized, afucosylated IgG1 monoclonal antibody targeting fibroblast growth factor receptor 2b (FGFR2b)
Ref: 3D-CLA1499
| Undefined size | To inquire |
Estimated delivery in United States, on Tuesday 17 Dec 2024
